Investigational Drug Information for Savolitinib
✉ Email this page to a colleague
What is the development status for investigational drug Savolitinib?
Savolitinib is an investigational drug.
There have been 34 clinical trials for Savolitinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 8th 2021.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Carcinoma, and Carcinoma, Renal Cell. The leading clinical trial sponsors are AstraZeneca, Hutchison Medipharma Limited, and Parexel.
There are fourteen US patents protecting this investigational drug and two hundred and ninety-four international patents.
Summary for Savolitinib
| US Patents | 14 |
| International Patents | 294 |
| US Patent Applications | 82 |
| WIPO Patent Applications | 103 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 2 (2021-10-08) |
| Vendors | 42 |
Recent Clinical Trials for Savolitinib
| Title | Sponsor | Phase |
|---|---|---|
| Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment | Samsung Medical Center | Phase 2 |
| A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects | Parexel | Phase 1 |
| A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects | AstraZeneca | Phase 1 |
Clinical Trial Summary for Savolitinib
Top disease conditions for Savolitinib
Top clinical trial sponsors for Savolitinib
US Patents for Savolitinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Savolitinib | ⤷ Subscribe | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Subscribe |
| Savolitinib | ⤷ Subscribe | Compounds and methods for inhibiting JAK | Dizal (Jiangsu) Pharmaceutical Co., Ltd. (Wuxi, Jiangsu Province, CN) | ⤷ Subscribe |
| Savolitinib | ⤷ Subscribe | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Savolitinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Savolitinib | Australia | AU2017261372 | 2036-05-05 | ⤷ Subscribe |
| Savolitinib | Canada | CA3023278 | 2036-05-05 | ⤷ Subscribe |
| Savolitinib | China | CN107847398 | 2036-05-05 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
